AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice.
AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice.
复制标题
DOI：
10.1038/srep45525
复制
发表时间：
2017-03-31
影响因子：
4.6
通讯作者：
Baker OJ
中科院分区：
文献类型：
--
作者：
Wang CS;Maruyama CL;Easley JT;Trump BG;Baker OJ
舍格伦综合征（SS）是一种慢性炎症性自身免疫性疾病，其特征是外分泌腺分泌功能减弱。唾液过少的治疗仅限于使用唾液替代品和仅提供暂时缓解的药物。鉴于高度的需求和目前治疗的局限性，开发替代治疗以恢复功能至关重要。Resolvins（Rv）是一种高效的脂质介质，为更好地治疗炎症性疾病（如SS）提供了一种可行的替代方案。本研究的目的是确定用阿司匹林触发的RvD 1（AT-RvD 1）进行的全身预防性治疗是否减少NOD/ShiLtJ SS样小鼠的炎症并保留分泌功能。我们的结果表明，用AT-RvD 1全身治疗减少了雌性小鼠唾液上皮中疾病的进展，如下：（a）改善分泌功能，（B）降低促炎分子基因表达，（c）增加抗炎分子基因表达和（d）诱导M2巨噬细胞极化。最后，AT-RvD 1减少淋巴细胞浸润到唾液腺时，使用小剂量的类固醇，地塞米松，并促进组织愈合过程。
Sjögren’s syndrome (SS) is a chronic inflammatory autoimmune disease characterized by diminished secretory function of the exocrine glands. Treatments for hyposalivation are limited to the use of saliva substitutes and medications that provide only temporary relief. In light of the high degree of need and the limitations of current therapies, development of alternative treatments to restore functioning is essential. Resolvins (Rv), which are highly potent lipid mediators, offer a viable alternative for better treating inflammatory diseases such as SS. The goal of this study was to determine whether systemic preventive treatment with Aspirin-triggered RvD1 (AT-RvD1) reduces inflammation and preserves secretory functioning in NOD/ShiLtJ SS-like mice. Our results indicate that systemic treatment with AT-RvD1 diminishes the progression of the disease in salivary epithelium from female mice as follows: (a) improves secretory function, (b) reduces pro-inflammatory molecule gene expression, (c) increases anti-inflammatory molecule gene expression and (d) induces M2 macrophage polarization. Finally, AT-RvD1 decreases lymphocytic infiltration into the salivary glands when used with small doses of the steroid, dexamethasone, and promotes the tissue healing process.